Anavex Life Sciences, a New York-based biopharmaceutical company, develops therapeutics for neurodegenerative diseases and employs 40 staff. Its lead compound, ANAVEX 2-73, targets Alzheimer's and Parkinson's diseases.
AVXL has been in the news recently: Anavex Life Sciences (AVXL) is set to release its quarterly earnings report on August 12, 2025. Meanwhile, 180 Life Sciences Corp. (ETHZilla) raised $156 million through convertible notes, resulting in a 54% surge in its shares after-hours.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
